Allarity Therapeutics Appoints Jeff Ervin as New CFO.

Allarity Therapeutics has appointed Jeff Ervin as its new Chief Financial Officer, replacing Alexander Epshinsky. Ervin brings nearly two decades of executive leadership experience across healthcare, biotech, and other sectors. He previously served as Co-Chief Financial Officer at DayDayCook and Chief Executive Officer at IMAC Holdings. Epshinsky will remain engaged with the company during a transition period.

Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company specializing in personalized cancer treatments, has appointed Jeff Ervin as its new Chief Financial Officer (CFO). Ervin succeeds Alexander Epshinsky, who will remain engaged with the company during a transition period. Ervin brings nearly two decades of executive leadership experience across healthcare, biotech, and other sectors.

Previously, Ervin served as Co-Chief Financial Officer at DayDayCook and Chief Executive Officer at IMAC Holdings. He also held a senior finance role at Medx Publishing. Currently, he serves on the board of directors of Cingulate Inc., a biopharmaceutical company focused on ADHD treatment. Ervin holds an MBA in Finance and Strategy from Vanderbilt University and a BS in Finance from Miami University.

“Jeff Ervin’s strong track record in public company leadership and financial management aligns well with our mission to accelerate the clinical development of stenoparib,” said Thomas Jensen, CEO of Allarity Therapeutics. “His extensive experience will be highly valuable in supporting a sustainable financial strategy and the execution of our expanding clinical trial activities.”

Stenoparib, the company’s lead drug candidate, is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. It has the potential to treat various cancers by inhibiting PARP and blocking the WNT signaling pathway. Allarity has secured exclusive global rights for the development and commercialization of stenoparib.

Allarity uses its Drug Response Predictor (DRP®) technology to select patients expected to benefit from stenoparib. The DRP method is based on messenger RNA expression profiles from patient biopsies and has shown statistically significant predictions of clinical outcomes in numerous studies.

Ervin will work on a half-time basis initially, with the possibility of transitioning to full-time employment based on the company’s needs. This structure reflects Allarity’s focus on operational and financial efficiency.

This appointment is part of Allarity’s strategy to maintain financial flexibility and continue advancing stenoparib through clinical development. The company faces risks related to clinical trial timelines, regulatory approvals, and market conditions.

Reference List:
[1] https://finance.yahoo.com/news/allarity-therapeutics-announces-appointment-jeff-120000175.html